hypertension (23) . The lessons learned from the study of the natural history of SCD underscored the fact that this disease, which is caused by a single missense mutation in a gene whose expression is restricted to the hematopoietic system, can have wide-ranging manifestations and complications that affect every aspect of the life of afflicted patients.
Genetics of SCD
As mentioned above, pioneering studies by Pauling et al. established that SCD results from a defect in the hemoglobin molecule (7) . During the same year, the mode of inheritance of the disease was shown to be autosomal recessive (8) . The sickle mutation was characterized several years later by Ingram et al. as a glutamine-tovaline substitution at the sixth residue of the b-globin polypeptide (24) . Several decades later, the human globin genes were cloned, their DNA sequence was determined, the organization of the globin gene clusters was characterized, and a great deal of insight was provided into the mechanisms of their regulated expression (25) . Human hemoglobin is a tetrameric molecule that consists of two pairs of identical polypeptide subunits, each encoded by a different family of genes. The human a-like globin genes (ζ, a 1 , and a 2 ) are located on chromosome 16, and the b-like globin genes (ε, Gg, Ag, d, and b) are located on chromosome 11. Interestingly, the genes are present on both chromosomes in the same order in which they are expressed during development ( Figure 2 ). During fetal life, the predominant type of hemoglobin is Hb F (a 2 g 2 ). During the postnatal period, Hb F is gradually replaced by Hb A (a 2 b 2 ). Hb A2 (a 2 d 2 ) is a minor adult-type hemoglobin that accounts for less than 2.5% of the circulating hemoglobin in normal individuals in adult life. Upon completion of the switch from Hb F to Hb A, patients with disorders of the b-globin genes start manifesting the clinical features of their diseases. The prospect of therapeutic reactivation of Hb F production in adult life (see "Advances in the therapy of SCD") has been in large part responsible for the tremendous interest in the elucidation of the molecular mechanisms of the switch from fetal to adult hemoglobin production. This field of investigation, which has recently been reviewed (26) , led to approval by the FDA of the use of hydroxyurea for the treatment of patients with SCD.
Homozygosity for the sickle mutation (i.e., HbSS disease) is responsible for the most common and most severe variant of SCD. Several other genetic variants of SCD result from the interaction of different mutations of the human b-globin genes ( Table 1) . When the b S gene interacts with the b C gene, the resulting sickling disorder known as HbSC disease is typically very mild (14) . When a b S gene interacts with a b-thalassemia gene (a mutant b-globin gene that either fails to produce normal b-globin mRNA or produces it at markedly decreased levels), the severity of the resulting sickling disorder depends on the severity of the coinherited b-thalassemia mutation. When the coinherited b-thalassemia gene is completely inactive (i.e., b 0 -thalassemia), the resulting sickling disorder known as Sb 0 -thalassemia tends to be of severity similar to that of homozygous HbSS disease (27) . In contrast, when the coinherited b-thalassemia gene is partially active (i.e., b + -thalassemia), the resulting sickling disorder known as Sb + -thalassemia can have a spectrum of clinical severity. If the b + -thalassemia mutation is mild, as is commonly the case in people of African descent, the resulting Sb + -thalassemia tends to be clinically mild. In contrast, if the b + -thalassemia mutation is severe, as is commonly the case in the Mediterranean populations, the clinical sickling disorder tends to be moderate (28) .
Advances in the pathophysiology of SCD
In addition to the obvious shape changes that result from the formation of intracellular hemoglobin polymers, the polymers can have a direct impact on the rbc plasma membrane, leading to the extracellular exposure of protein epitopes and glycolipids that are normally found inside the cell (Figure 3 ). These changes and the aberrant expression of adhesion molecules on stress reticulocytes likely explain the increased adherence of sickle rbc to vascular endothelium. Although the increased propensity of sickle rbc to stick to one another was noted many years before the field of cell adhesion was even conceptualized at the molecular level, pioneering independent studies by Hebbel, Hoover, and their colleagues demonstrated that sickle rbc were more apt than normal rbc to adhere to endothelial cells in vitro (29, 30) . During the two decades that followed, multiple studies implicated virtually all major adhesion pathways in the interactions between sickle cells and endothelial cells. These pathways include those involving the integrins (a 4 b 1 , a V b 3 ) (31-33) and their receptors; immunoglobulin family members (VCAM-1, ICAM-4) (34, 35) ; the endothelial selectins (36, 37) ; soluble adhesion proteins such as thrombospondin (38) , fibrinogen (39) , fibronectin (40) , von Willebrand factor (41, 42) ; and other exposed membrane components such as Band3 and sulfated glycolipids (43, 44) . Thus, inasmuch as sickle adhesion to the endothelium plays a role in sickle cell vasoocclusion, the presence of such diverse mechanisms of adhesion presents an enormous challenge for delineating physiologically relevant therapeutic targets. Interestingly, recent studies have suggested that targeting a specific adhesion pathway may be sufficient to reduce vasoocclusion (33, 37, 45) .
The studies of the pathophysiology of SCD have been facilitated by the development of a number of mouse models that express either a mixture of mouse globins with Hb S, a super-sickling hemoglobin (e.g., SAD, NY1, S-Antilles mice), or human globin chains exclusively (e.g., Berkeley, NY1KO mice) (46) . The severity of the phenotype of these transgenic mice depends on the presence of mouse globin chains, the mean corpuscular hemoglobin concentration (MCHC), and the presence of human Hb F. Although mice that express the human globin chains exclusively Sickle erythrocytes. Peripheral blood smear from a patient with SCD obtained during a routine clinic visit. The smear shows classical sickle-shaped (arrows) and various other misshaped erythrocytes (arrowheads). The image was obtained from an air-dried smear using differential interference contrast (DIC) microscopy with an Olympus BX61WI work station equipped with a LUMPlanFI ×60 numerical aperture 0.90 ∞ objective (Olympus) and a CoolSnaP HQ camera (6.6 mm 2 pixel, 1,392 × 1,040 pixel format) (Roper Scientific). Scale bar: 10 mm.
have a much more severe phenotype that closely mimics the major features of the human disease, all transgenic sickle mice exhibit pathological features of the disease, either spontaneously or in an inducible manner (46, 47) .
As in the human disease, there is a clear role for inflammatory mediators in the pathogenesis of disease in murine models of SCD (48) (49) (50) (51) (52) . Inflammation is likely triggered by the abnormal erythrocyte membrane and the presence of chronic hemolysis. Dense sickle cells that become dehydrated after several rounds of sickling expose their annexin V-binding phosphatidyl serine on the outer layer of the plasma membrane (53, 54) . These negatively charged glycolipids can activate the coagulation cascade (55) , leading to the generation of tissue factor and thrombin, which in turn promote the inflammatory response. Chronic hemolysis, on the other hand, leads to the release of plasma-free hemoglobin, which can scavenge NO and result in endothelial dysfunction (56) . Moreover, the release of heme iron from lysed rbc is a major cause of oxidative stress that can induce redox-sensitive transcription factors such as NF-kB and activator protein-1. These transcription factors in turn induce the expression of E-selectin, VCAM-1, and ICAM-1 and the recruitment of adherent leukocytes in venules (51) .
The presence of adherent leukocytes in small postcapillary venules is emerging as a key factor that contributes to vasoocclusion during SCD (57, 58) ( Figure 4 ). Leukocytes are large cells that are rigid and not easily deformed as a result of a high viscoelastic coefficient (59) . These physical properties endow leukocytes with a greater potential than discoid or sickle-shaped rbc (which would lie flat along the endothelium) to promote vascular obstruction. It has been known for many years, as a result of microdynamic measurements, that leukocyte recruitment in cat mesenteric venules can lead to a decrease in the effective diameter of the blood vessels and an increase in blood flow resistance due to obstruction of the lumen by wbc (60) . In addition, sickle rbc have been shown to interact directly with adherent wbc in a mouse model of vasoocclusion induced by surgical trauma and TNF-a, leading to reduced blood flow and death of the mouse (49) . Leukocyte adhesion was shown to be critical in this process,
Figure 2
Chromosomal organization of the a-and bglobin gene clusters. (A) The genes of the b-globin gene cluster (ε, Gg, ag, d, and b) are present on chromosome 11 in the same order in which they are expressed during development. The b-locus control region (b-LCR) is a major regulatory element located far upstream of the genes of the cluster that is necessary for the high level of expression of those genes. (B) The genes of the a-globin gene cluster (ζ, a1, and a2) are present on chromosome 16, also in the same order in which they are expressed during development. HS-40 is a major regulatory element located far upstream of the genes of the cluster that is necessary for their high level of expression. (C) During fetal life, Hb F (a2g2) is the predominant type of hemoglobin. Hemoglobin switching refers to the developmental process that leads to the silencing of g-globin gene expression and the reciprocal activation of adult b-globin gene expression. This results in the replacement of Hb F by Hb a (a2b2) as the predominant type of hemoglobin in adult life. since flow reductions and death were prevented in mice deficient in both P- and E-selectins, key adhesion molecules mediating leukocyte rolling and adhesion (49, 61) . Moreover, in vitro studies have revealed that human sickle cells can directly bind to activated neutrophils (62) . Recent studies using high-speed fluorescence digital videomicroscopy suggest that most interactions between rbc and wbc in vivo are mediated by adherent neutrophils (63) . As leukocyte adhesion plays a key role in vasoocclusion, it thus offers an attractive therapeutic target for this disease and is consistent with several clinical studies derived from the CSSCD cohort in which high leukocyte counts correlated with mortality (14), acute chest syndrome (16) , stroke (17, 64, 65) , and poor prognosis later in life when identified in infants with SCD (66) .
Advances in the diagnosis of SCD
The diagnosis of SCD is usually simple and rarely poses a major challenge. Although the sickle-shaped rbc that gave the disease its name are not always present in the patient's blood film, the characteristic migration of Hb S by gel electrophoresis is sufficient to make a diagnosis of a sickling disorder. Gel electrophoresis allows a definitive diagnosis of some but not all sickling genotypes. For example, when Hb A is present in the blood of a patient with SCD at a lower level than Hb S, this is indicative of HbSb + -thalassemia (Table 1) . However, the distinction between HbSb 0 -thalassemia and homozygous HbSS can be much more challenging to make when no Hb A is detected by gel electrophoresis. In such situations, the diagnosis of HbSb 0 -thalassemia is suggested by an elevated Hb A 2 level and a low mean corpuscular volume. Fortunately, there are a number of excellent reference laboratories in the US where a definitive molecular diagnosis can be made in essentially every patient with a hemoglobin disorder.
The major challenge in the diagnosis of sickling disorders is to identify the disease during the prenatal period, at a time when such information would be critically important in enabling a couple at risk to make an informed decision about potential termination of pregnancy. The marked differences in the expected clinical severity of the different sickling disorders discussed above should be taken into consideration when making such decisions. Before the advent of molecular diagnostics, the only way to make a diagnosis prenatally was to obtain a fetal blood sample for analysis, which could only be performed after the 20th week of pregnancy. By that time, the pregnancy is already too advanced to make it possible to terminate safely. With the advent of DNA diagnostics, it has become possible to make definitive diagnoses of the different sickling disorders during the first trimester by analyzing fetal DNA obtained by chorionic villous biopsy (67) . The molecular diagnostic technology is being pushed further to allow the diagnosis to be made from a small number of fetal cells that can be harvested from the maternal circulation (68) .
Advances in the therapy of SCD
Induction of Hb F. A large number of epidemiological, clinical, and laboratory observations have converged to support the notion that Hb F administration can ameliorate the clinical severity of SCD. Patients with SCD from the eastern provinces of Saudi Arabia (69) and from India (70) typically have a very mild sickling disorder associated with high levels of Hb F. Furthermore, the CSSCD identified Hb F as a prognostic factor for several sickle cell complications, including painful events (19) , acute chest syndrome (16) , and death (14) . Elegant laboratory studies conducted many years earlier had demonstrated that Hb F interferes with the polymerization of deoxygenated Hb S in vitro (71) . Based on all these observations, it was proposed that pharmacological induction of Hb F production may be an effective therapeutic strategy for ameliorating the severity of SCD. When the different globin genes were cloned in the late 1970s (72) and the mechanisms responsible for their regulation were elucidated during the 1980s (73, 74) , it became clear that epigenetic factors such as DNA methylation and histone acetylation played important roles in the developmental regulation of globin gene expression (75) (76) (77) . Thus, it was proposed that pharmacological agents that alter the epigenetic configuration of the g-globin genes may provide a viable therapeutic approach to the induction of Hb F. 5-Azacytidine. 5-Azacytidine was the first agent to be used to induce Hb F expression via epigenetic silencing of the g-globin genes in adult life. The rationale for this approach was based on the discovery that the actively transcribed adult b-globin genes are hypomethylated and the nontranscribed fetal g-globin genes are hypermethylated in adult life. In contrast, the adult b-globin genes are hypermethylated and the g-globin genes are hypomethylated in fetal life (75, 76) . 5-Azacytidine was shown to induce very high levels of Hb F in anemic baboons (78) . Its ability to stimulate Hb F production was also demonstrated in a small number of patients with SCD and b-thalassemia (79, 80) . In spite of these promising results, this drug was never tested in large-scale clinical trials because of concerns about potential carcinogenicity. a "Typical" refers to the most common presentation of a particular sickling genotype. It should be noted that in many patients, the genotype does not accurately predict the clinical phenotype. B assessed by gel electrophoresis. Hb a2, minor adult hemoglobin.
Hydroxyurea. The clinical development of hydroxyurea as an agent that induces Hb F production in SCD provides a vivid illustration of how scientific discoveries can be translated into therapies that improve the outlook for patients afflicted with a debilitating disease. Interestingly, controversy over the mechanism of induction of Hb F by 5-azacytidine provided the motivation for a study in which hydroxyurea, an S phase-specific chemotherapeutic agent that does not inhibit DNA methyltransferase, was shown to result in a marked increase in Hb F levels in baboons (81) . Hydroxyurea is an inhibitor of ribonucleotide reductase that had been in use for many years in the treatment of myeloproliferative disorders. It is an orally available drug that is relatively well tolerated and simple to use. After the demonstration of its ability to induce Hb F production in baboons, hydroxyurea was tested in a number of small clinical trials in adults with SCD (82) (83) (84) . A larger MSH study showed a marked decrease in the frequency of painful crises and acute chest syndrome and a reduction in transfusion requirements and hospitalizations in adults with moderate to severe SCD after hydroxyurea treatment (85). After 9 years of follow-up, patients with SCD treated with hydroxyurea were shown to have improved survival (86) . Other studies demonstrated the clinical efficacy and short-term safety of hydroxyurea in children with SCD (87-89).
Although hydroxyurea was shown to have Hb F-inducing activity similar to that of 5-azacytidine in anemic baboons and patients with SCD, its molecular targets and mechanism(s) of action are still not fully elucidated. It was originally proposed that hydroxyurea may elevate Hb F levels by accelerating erythroid differentiation in the bone marrow, leading to the appearance of "fetal-like" cells in the peripheral blood (25) . More recent studies have shown that hydroxyurea generates NO in vivo, which results in the activation of the NO/cGMP signaling pathway and the upregulation of g-globin gene expression in patients with SCD (90) . Hydroxyurea has other effects that may also benefit patients with SCD. For example, hydroxyurea was shown to decrease the adhesion of sickle cells to endothelium and to decrease the expression level of soluble VCAM-1 (91, 92) . Owing to its myelosuppressive activity, hydroxyurea reduces circulating wbc counts and likely the number of adherent leukocytes recruited to the wall of small venules. The reduc- tion of wbc counts was correlated with the clinical benefit from hydroxyurea (93) . It is still not entirely clear how much of the clinical benefit from hydroxyurea could be attributed to its effect on Hb F levels compared with its other activities.
Butyrate. Concerns over the potential for serious side effects of chemotherapeutic agents such as 5-azacytidine and hydroxyurea has stimulated the continuation of the search for safe and effective inducers of Hb F production. Butyrate, a short-chain fatty acid that inhibits histone deacetylase (HDAC), was shown to stimulate embryonic or fetal globin gene expression in chicken, mice, and baboons (94) (95) (96) . When arginine butyrate was administered to patients with SCD intermittently (four days every four weeks), it resulted in sustained induction of Hb F production in a majority of patients (97) . In spite of the considerable promise of this agent in the treatment of SCD, the difficulty of administrating large volumes of this drug through central venous catheters poses a major therapeutic challenge. It is unlikely that the full potential of butyrate and other HDAC inhibitors will be realized until an oral compound is identified that has the same efficacy as butyrate.
Decitabine. The recent introduction of decitabine (5-aza-2deoxycytidine), a new analog of 5-azacytidine that does not incorporate into RNA, has resulted in renewed interest in the use of DNA hypomethylation therapy for the induction of Hb F production in SCD. In recent small-scale clinical trials in patients with SCD, treatment with decitabine resulted in significant increases in mean g-globin synthesis, Hb F levels, and the number of F cells (rbc that contain Hb F) (98-100). Interestingly, increased Hb F levels were observed in 100% of patients with SCD who received decitabine, including patients who had previously failed to respond to hydroxyurea. The increase in the levels of Hb F was associated with significant improvement in several factors that are important in the pathophysiology of vasoocclusion, including rbc adhesion, endothelial damage, and activation of the coagulation pathway (100) . Larger and longerterm studies are needed to confirm the efficacy and safety of decitabine in the treatment of SCD.
Bone marrow transplantation
The idea of replacing the bone marrow, which is the source of the defective sickle cells, with bone marrow that produces normal rbc is an intuitive therapeutic approach in SCD. However, for many years, such an approach was considered too risky for a nonmalignant disorder such as SCD, since the mortality of the procedure itself was around 20%. The reduction in mortality following bone marrow transplantation (BMT), resulting from recent advances in immunosuppressive therapy and supportive care and the fact that long-term survival of patients with b-thalassemia after BMT was shown to be greater than 90% (101), resulted in renewed interest in this therapy for SCD. Clinical trials that were conducted in children with SCD in Europe and the US showed greater than 90% long-term survival (102) (103) (104) . A major limitation in the use of BMT for the treatment of SCD is the fact that a matched sibling donor is available to less than 15% of patients who are suitable candidates for transplantation (105) . In an effort to increase the availability of sources of hematopoietic stem cells for transplantation, clinical trials are being conducted to evaluate cord blood transplantation in the treatment of SCD (106). To date, very few transplantation procedures have been performed in adults with SCD because of concerns that the morbidity and mortality of BMT is higher in adults than in children. The use of nonmyeloablative BMT to reduce peritransplant morbidity and mortality has been associated with a very high graft rejection rate (107) . BMT is the only curative therapy for SCD, and the major challenge is to make it more widely available to patients with a severe disease phenotype.
Impediments that limit the impact of the advances in SCD
In spite of the fact that hydroxyurea has been shown to improve both survival and the quality of life in patients with SCD, only a small fraction of eligible patients with SCD in the US are currently receiving hydroxyurea (108, 109) . Although the reasons for the reluctance to use hydroxyurea are not entirely clear, there are many potential contributing factors. These include patient
Figure 4
Sickle cell vasoocclusion. abnormal, sickle rbc induce the expression of inflammatory and coagulation mediators, leading to the activation of the vascular endothelium. Sickle rbc themselves may also stimulate endothelial cells directly by adhesion. The stimulated endothelial cells are poised to recruit rolling and adherent leukocytes in venules by expressing chemokines and cell adhesion molecules such as the selectins and immunoglobulin family members. activated, firmly adherent neutrophils capture circulating discoid and sickle-shaped rbc, leading to transient episodes of vascular occlusions that are initiated in the smallest postcapillary venules. Interactions between rbc and leukocytes tend to occur at vessel junctions, where leukocyte recruitment is the most active. In sickle mice, vasoocclusion can be prevented by the inhibition of leukocyte adhesion or the inflammatory response. The large arrow indicates the direction of blood flow.
concerns about a drug that is used primarily to treat cancer, physician concerns about potential long-term mutagenic effects, lack of familiarity of primary care providers with the use of a chemotherapeutic agent, and resistance among patients with SCD to use therapies that are perceived to be experimental in nature. Careful investigation into the impediments to the use of hydroxyurea is necessary in order to realize the full potential of this important therapeutic advance.
Prenatal diagnosis is another area in which the development of important new technology has had a very limited impact in SCD. In spite of the fact that DNA diagnostics have made it possible to identify an affected fetus much earlier during pregnancy, the impact of these advances on the number of new births with SCD in the US has been extremely small. In contrast, the same technology has had a very large impact on the number of new births with b-thalassemia in Mediterranean regions including Greece, Cyprus, and Sardinia (110) . Although the reasons for the differences in the impact of the same technology in these closely related disorders have not been investigated, it is conceivable that they are a reflection of the fact that a majority of patients with b-thalassemia die from iron overload before the third decade of life, while survival of patients with SCD into the fifth, sixth, and even seventh decades of life is not unusual. The reluctance to terminate an affected pregnancy may also be motivated by cultural and ethnic factors that have not received adequate attention. It is sobering to keep in mind that the one intervention that has had the largest impact on the natural history of SCD during the last few decades is the introduction of penicillin prophylaxis during childhood (13) . This should serve as a reminder that important therapeutic advances are bound to have a very limited impact on the natural history of any human disease unless they are widely accepted by the patients they are intended to help.
Future directions
Future of diagnostics in SCD. As discussed above, the molecular methods of identifying the sickle mutation in utero and after birth are well established and widely available. However, although the same sickle mutation in the b-globin gene is responsible for the spectrum of the pathophysiology of the sickling disorder, the clinical manifestations of the disease are extremely heterogeneous. Many factors that contribute to this heterogeneity, such as an interaction of the b C gene and the b-thalassemia gene, are well known. Other factors such as the Hb F levels and the coinheritance of a-thalassemia have also been known to modulate the clinical severity of sickling disorders for many years (69, 70, 111) . Other genetic determinants that contribute to the variability of Hb F levels were identified outside the b-globin gene cluster and mapped to two different chromosomes (112, 113) . More recent studies have demonstrated that the gene responsible for the variability in Hb F levels that was previously mapped to chromosome 6p23 (112) is cMYB (114) . As the understanding of the pathophysiology of the disease evolves, the number of potential epistatic genes (i.e., modifying genes) increases. Thus, mutations or polymorphisms that have an impact on cell adhesion, thrombosis, rbc dehydration, and inflammation are likely in candidate epistatic genes in SCD. As is the case with the coinheritance of a-thalassemia, some of these genetic determinants might increase the risk of some complications and decrease the risks of others. A number of studies have investigated the potential effects of candidate modifying genes that are implicated in the pathophysiology of the dis-ease (e.g., methylenetetrahydrofolate reductase and the pathogenesis of avascular necrosis [ref. 115] , factor V R485K and the risk of venous thrombosis [ref. 116] , and UDP glucuronosyltransferase-1 polymorphism and serum bilirubin levels [ref. 117] ). Other investigators are using an unbiased genetic approach that consists of the analysis of hundreds of SNPs in a large number of patients to identify genes that increase the risk of a particular complication. Using such an approach, Sebastiani and colleagues recently identified 31 SNPs in 12 genes that interact with Hb F to modulate the risk of stroke (118) . In the future, such biased and unbiased approaches may make it possible to identify a genetic blueprint in a particular patient that defines his/her risk of developing any of the known complications of SCD. It might even be possible at some point to use this information to implement therapeutic interventions before the complications develop.
Future of therapeutics in SCD. Gene therapy offers enormous promise as a potential curative therapy for SCD, but concerns over the safety of random genomic insertion must first be resolved (119) . Preclinical studies in mice have provided the proof of principle that transduction of bone marrow stem cells with lentiviral vectors that express a b-globin gene can prevent Hb S polymerization in vivo (120, 121) . The wide range of abnormalities engendered by the sickle cell mutation offers several other opportunities for therapeutic interventions. For example, the NIH Road Map is supporting ongoing investigations in which high-throughput screening approaches are used to discover novel low-molecular-weight compounds that can alter key aspects of the disease, including hemoglobin polymerization, expression of Hb F, and leukocyte adhesion. Current clinical trials are evaluating the efficacy of Ca 2+ -sensitive Gardos channel inhibitors (e.g., ICA-17043), with or without hydroxyurea, in preventing dehydration of erythrocytes (122) . Vasoactive drugs (e.g., NO, sildenafil, endothelin antagonists) are being evaluated for the treatment of pulmonary hypertension. Statins are of potentially great interest since they can increase NO production and reduce leukocyte adhesion (123, 124) . Antiinflammatory drugs that inhibit NF-kB and the upregulation of adhesion molecules have shown promise in pilot clinical studies (125) . Intravenous gammaglobulins are currently under clinical evaluation following a study demonstrating a dosedependent reduction in leukocyte adhesion and in the number of interactions between rbc and wbc, accompanied by improvements in microcirculatory blood flow and survival of sickle transgenic mice (126) . Furthermore, there is growing interest in the prevention and treatment of vasoocclusion by novel selectin antagonists since they appear to participate in multiple pathways involved in sickle vasoocclusion, including the adhesion of leukocytes, rbc, and platelets to the endothelium and to each other (127) . Almost a century after SCD was first described, we may be at the dawn of a new era in which a physician might be able to use genetic information to select one or more drugs that target specific aspects of disease pathophysiology that are relevant to a particular patient with SCD.
